Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD

The psychedelic compound-based clinical stage drug research and development sector is up by 12.3% in the last 2 weeks in response to the FDA's recent release of a positive draft guidance for developing psychedelic treatments last week.

The 6 largest stocks in the Psychedelic Drug Stocks Index are ranked below as to their performances so far this month (i.e. MTD) and YTD:

  1. Atai (ATAI): UP 18.6% MTD; DOWN 20.9% YTD
  2. Mind Medicine (MNMD): UP 18.2% MTD; UP 93.6% YTD
  3. Compass Pathways (CMPS): UP 15.1% MTD; UP 22.0% YTD
    • Compass is a pre-revenue biotech company that's nowhere close to commercializing its flagship therapy, COMP360, which is being investigated for treatment-resistant depression (TRD), among a smattering of other potential indications like post-traumatic stress disorder (PTSD),
    • is focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin and
    • analysts on Wall Street are figuring, on average, that its shares will explode by over 300% to reach around $42.30 within the next 12 months (Source)
    • current short interest: 15% A high short interest signals that investors have become more bearish and may be getting ready to sell and, as such, that it may be time to liquidate a long position.
  4. Seelos (SEEL): UP 10.8% MTD; UP 104.6% YTD
  5. Incannex Healthcare (IXHL): UP 9.3% MTD; DOWN 28.6% YTD
    • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
    • Incannex has received approval for a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis. (Source)
    • current short interest: 0%
    • Read: Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
  6. GH Research (GHRS): UP 8.3% MTD; UP 34.8% YTD
    • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine,
    •  H.C. Wainwright analyst Patrick Trucchio believes that if positive results are achieved in GHRS' proof-of-concept clinical study related to a drug for Treatment Resistant Depression and it receives FDA approval then it could generate annual revenues of more than $3 billion. He has a Buy rating on the shares backed by a $45 price target which represents a 12-month share appreciation of approximately 250%. (Source)
    • current short interest: 9.8%
    • Read: GH Resources: Focus On Treatment-Resistant Depression Paying Off 

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.


The munKNEE Psychedelic Drug Stocks Index is UP 12.3% MTD and is now UP 25.1% YTD.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks. It is UP 10.9% MTD and is now UP 9.7% YTD.

More By This Author:

These 15 AI Stocks Are Up 28% In Last 2 Months; Up 51% YTD
These 8 Fringe ETF Returns Ranged From +13% To -5% Last Week
These 9 Artificial Intelligence Stocks Are In A Bubble: Up 161% YTD

Disclosure: None

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.